跳到正文
原文
Medical Xpress·· 24 天前精选AI 评分65

Northwestern Medicine 研究识别出可能驱动湿性AMD等眼病异常血管生长的巨噬细胞亚群 MoPOMs

Previously unrecognized immune cells may drive harmful blood vessel growth in blinding eye diseases

AI 导读

Northwestern Medicine 团队整合 173 份人眼与小鼠眼组织样本、近 10 万个免疫细胞的数据,识别出此前未被认识的巨噬细胞亚群 MoPOMs,其在湿性年龄相关性黄斑变性(AMD)和增殖性糖尿病视网膜病变中富集。

推荐理由

研究在人与小鼠眼组织中定位到与异常血管生长相关的巨噬细胞亚群,为抗VEGF应答不佳的患者提示了一条新靶点线索。

正文
Understanding how immune cells can drive blindness
Credit: Journal of Clinical Investigation (2026). DOI: 10.1172/jci205838

A Northwestern Medicine study has identified a previously unrecognized population of immune cells that appears to fuel harmful blood vessel growth in multiple blinding eye diseases, according to the study published in the Journal of Clinical Investigation. The discovery could open the door to new treatments for patients who don't respond to existing therapies, said the study's senior author Jeremy Lavine, M.D., Ph.D., assistant professor of ophthalmology.

In the study, Northwestern Medicine investigators analyzed nearly 100,000 immune cells from human and mouse eye tissues, combining data from 173 samples across multiple eye diseases. They identified a distinct subtype of macrophage, dubbed monocyte-derived pro-angiogenic ocular macrophages (MoPOMs), which was consistently enriched in subjects with eye diseases that feature harmful blood vessel growth, including wet age-related macular degeneration (AMD) and proliferative diabetic retinopathy.

Wet AMD and diabetic retinopathy are among the leading causes of vision loss worldwide, according to National Institutes of Health data. Both diseases are commonly treated with drugs that block vascular endothelial growth factor (VEGF), a protein that promotes blood vessel formation. While anti-VEGF therapies have transformed care, many patients eventually experience diminishing responses or treatment resistance, Lavine said.

"We hypothesized that a joint escape mechanism existed where macrophages could potentially be targeted in both diseases for patients who are treatment resistant," Lavine said. "Outside of the eye in cancer and other diseases, macrophages can promote abnormal angiogenesis. There's not only evidence within the eye, but also outside the eye."

To identify the cell population, the team combined data from human patients with wet AMD and diabetic eye disease with mouse models of both conditions.

Using RNA sequencing, the investigators found that disease-linked macrophages express genes linked to blood vessel overgrowth, including SPP1, FABP5 and IL7R, which are largely absent from healthy eye tissue.

Next, the investigators tested whether these cells were merely associated with disease or actively driving it. In mouse models, selectively depleting IL7R-positive macrophages reduced abnormal blood vessel growth by more than 40%, demonstrating that the cells are required for disease development.

To determine whether similar cells exist in patients, the investigators performed high-resolution spatial transcriptomics on donated human eye tissue. The spatial analysis confirmed that the macrophages were located almost exclusively near choroidal neovascular membranes—the destructive lesions responsible for vision loss in wet AMD.

"We were shocked to find that 98% of the macrophages were from the patients with wet AMD," Lavine said. "Of those 98%, 84% were specifically in the lesions, and 12% were right next to the lesion."

The team also identified MMP14, a protein produced by the macrophages and other cells within neovascular lesions, as a potential therapeutic target. Treating mice with an MMP14 inhibitor reduced lesion size by more than 50%.

Suppressing the signals produced by these cells may help prevent vision-threatening blood vessel growth, Lavine said, offering a new potential treatment option for patients facing blindness.

"Right now, treatment targets a single molecule to inhibit angiogenesis for these patients," Lavine said. "Rather than inhibiting these pathways one at a time, we hope that we can inhibit the cells that are trying to drive angiogenesis through multiple mechanisms, which would be more effective than a single pathway."

Future research will focus on translating the findings into potential therapies, Lavine said.

Publication details

Andrew P. Voigt et al., Monocyte-derived pro-angiogenic ocular macrophages identified by spatial transcriptomics are essential for choroidal neovascularization, Journal of Clinical Investigation (2026). DOI: 10.1172/jci205838

Journal information: Journal of Clinical Investigation

Who's behind this story?

Lisa Lock

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Previously unrecognized immune cells may drive harmful blood vessel growth in blinding eye diseases (2026, October 26) retrieved 26 October 2026 from https://medicalxpress.com/news/2026-10-previously-unrecognized-immune-cells-blood.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com